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Diabetes mellitus (DM) and abnormal glucose tolerance (IGT) are common in cystic fibrosis (CF). The loss of pancreatic h-cells due to
pancreatic fibrosis is thought to be one of the principal causes of diabetes in CF, but the aetiology of DM remains somewhat puzzling.
Genetic factors may contribute to the development of CF related diabetes (CFRD). The purpose of this study was to investigate the role of
polymorphisms in six genes on IGT or DM incidence. PCR and dHPLC were used to screen DNA samples for polymorphisms. Using 2-h oral
glucose tolerance tests, 163 adult pancreatic insufficient CF patients have been subdivided in 3 groups: 54 NGT (normal glucose tolerance),
33 IGT and 76 CFRD. We found the first evidence for the association between CFRD and UCSNP-19 polymorphism in the CAPN10 gene.
The UCSNP-19 genotype distribution differed significantly between NGT, IGT and CFRD groups. The difference reflected an increase in the
22 genotype (3 copies of 32-bp sequence) in IGT and CFRD patients ( p =0.05). Odds ratio for the homozygote 22 versus homozygote 11
was 3.4 ( p =0.02). All allele and genotype distributions for the other polymorphisms were similar in the three groups. In conclusion, our
observations suggest that UCSNP-19 of CAPN10 may be involved in the pathogenesis of diabetes in CF.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Calpain 10; Cystic fibrosis; dHPLC; Diabetes mellitusCystic fibrosis (CF) (MIM 219700) is a common
inherited disease mainly affecting the Caucasian population.
CF is characterised by abnormality in water and chloride
transport through the epithelium in sweat glands, the
pancreas, lungs, and intestines. This results in hyperviscos-
ity of ductular secretions. In the pancreas, CF culminates
with obstruction and fibrosis. Pancreatic involvement in CF
is common, with most patients developing gland fibrosis
and exocrine insufficiency. Diabetes and abnormal glucose
intolerance are also frequent in CF, affecting almost 50% of
patients over the age of 18 [1]. The aetiology of diabetes
remains somewhat puzzling. Decreased insulin secretion has1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.09.011
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E-mail address: bienvenu@cochin.inserm.fr (T. Bienvenu).been well documented and occurs even in CF patients with
normal glucose tolerance (NGT). The principal defects that
cause decreased insulin secretion are pancreatic fibrosis and
fatty infiltration of h-cells leading to progressive destruction
of the pancreatic islet architecture [2,3]. However, autopsy
studies do not correlate percentage of damaged islets with
development of diabetes [4,5]. Thus other defects must be
involved to account for the high incidence of abnormal
glucose tolerance in this population. Recent studies have
documented decreased insulin sensitivity in CF patients
with impaired glucose tolerance and with CF-related
diabetes (CFRD) [6,7]. Involvement of insulin resistance
is related to several mechanisms, including recurrent or
chronic lung infections, subclinical hepatic fibrosis, increase
in counter-regulating hormones, increased levels of cyto-
kines (interleukin and TNF-a), and, in patients with
diabetes, glucotoxicity. However, controversy exists regard-s 5 (2006) 47 – 51ed by Elsevier B.V. All rights reserved.
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reports of normal, enhanced, or decreased insulin action [7–
10]. The clinical and pathological similarities of CFRD with
type 2 diabetes, a disease which is associated with
significant increase in peripheral insulin resistance, impaired
insulin secretion and genetic risk factors [11], the absence of
correlation between the CFTR mutations and diabetes in CF
patients with pancreatic insufficiency phenotype, and the
presence of insufficient pancreatic adult patients with NGT
suggest that genetic factors different from the CFTR
genotype contribute to the development of CFRD. More
than 60 candidate genes have been identified as type 2
diabetes-related genes, which are related to insulin action,
insulin secretion and lipid metabolism. We therefore
analysed several candidate genes that may confer suscepti-
bility through involvement in inflammation which may have
important role in the pathogenesis of CF. Previous studies
provided a link between an increase in the expression and
the plasma concentration of a proinflammatory cytokine and
insulin resistance [12,13]. Our selection included the IL-6,
TNF-a, Peroxisome Proliferator-Activated Receptor gamma
(PPARc), Kir6.2, IL-18 polymorphisms. In addition, calpain
10 (CAPN10) which has been reported to be linked with
type 2 diabetes with the G>A polymorphism (UCSNP-43)
or the T>C polymorphism (UCSNP-44) in certain popula-
tion groups was also analysed [14]. Therefore, this study
was designed to investigate whether polymorphism(s) in six
candidate genes are associated with diabetes in CF patients.1. Subjects and methods
1.1. Subjects
We recruited 163 unrelated adult CF patients (80
female, 83 male) (aged >18 years) who were pancreatic
exocrine-insufficient attending the adult CF clinic at
Cochin Hospital in Paris. All patients gave written
informed consent. Patients with pulmonary exacerbations
requiring oral or intravenous antibiotic therapy in the past
4 weeks, recent commencement of enteral feeding,
patients on oral corticosteroid treatment, transplant or
pregnant patients were excluded from entering the study.
The 163 included patients underwent an oral glucose
tolerance test (OGTT) in the morning after an overnight
fast of at least 10 h. Glucose tolerance was classified
according to the World Health Organization criteria:
fasting plasma glucose of less than 7 mmol/L and 2
h post-load plasma glucose concentration <7.8 mmol/l for
normoglycemic CF patients (NGT); fasting plasma glu-
cose of less than 7 mmol/L and 2 h post-load plasma
glucose concentration between 7.8 and 11.1 mmol/L for
glucose intolerant CF patients (IGT); fasting plasma
glucose of greater than 7 mmol/L and/or 2 h post-load
plasma glucose concentration greater than 11.1 mmol/l for
Cystic-Fibrosis related diabetes (CFRD). FEV1 and bodymass index (BMI) were recorded at the time of OGTT.
Value of FEV1 was expressed as the percentage of
predicted value (% pred).
1.2. Molecular analysis
We selected the most representative SNP for each
candidate gene, according to two criteria: function and
frequency. We selected those SNPs for which there was
information on the function (such as A-308 of TNF-a;
UCSNP-43 of CAPN10; 70 G/A (E23K) of Kir6.2; 34 C>G
(P12A) of PPARc or which had already been shown to be
positively associated with more than one outcome in case–
control association studies (such as C-174 of IL-6; C-137 of
IL-18) [15–22]. Genomic DNA was extracted from
peripheral blood lymphocytes according to standard proto-
cols. Previously published polymerase chain reaction (PCR)
and restriction-digestion protocols were used to identify the
-174 C>G IL-6, 70 G>A (E23K) Kir6.2, and UCSNP-19
(g.7929indel32bp) CAPN10 polymorphisms [23–25]. We
developed denaturing high pressure liquid chromatography
(dHPLC) methods for IL-18 (-137 G>C), PPARc (34
C>G), TNF-a (-308 G>A) and CAPN10 (UCSNP-43,
UCSNP-44 and UCSNP-19) genotyping. dHPLC was used
because it is a good alternative to classical method in
genotyping SNPs. Advantages of this chromatographic
method were no restriction site needed and a reduced
technical times thanks to an automated injection. Reactions
were performed in a volume of 50 Al containing 50 mM
Tris–HCl (pH 8.4), 1.5 mM MgCl2, 200 AM of all four
deoxynucleotides, 0.5 mM each of the primers, 2.5 U of Taq
Polymerase (Gold; Applied Biosystems, Foster City, CA,
USA) and 100 ng template DNA. Primer sequences are
available on request. Thirty-five cycles were then performed
with denaturation for 30 s at 94 -C, annealing for 30 s at 57
-C (TNF-a) 58 -C (IL-18, PPARc, CAPN10) and
extension for 30 s at 72 -C. The DNA synthesis step of
the final cycle was extended to 7 min. For dHPLC analysis,
the amplified DNAwas heated at 94 -C for 7 min, and at 55
-C for 40 min to favour formation of heteroduplexes.
Variant analysis was performed by using dHPLC (Wave
DNA fragment analysis system, DNAsep column; Trans-
genomics, Santa Clara, CA, USA). dHPLC conditions were
chosen according to the Wavemaker program (Transgenom-
ics). PCR products were subjected to chromatography using
appropriate temperatures and acetonitrile gradient at a flow
rate of 0.9 mL/min, and those showing an abnormal dHPLC
profile were initially sequenced on an automated sequencer
(ABI 377; Applied Biosystems, Foster City, CA, USA)
using the Dye Terminator method. As the wild type and the
homozygous mutant can be eluted as a similar single
homoduplex peak, mixing with a known reference (wild
type) was systematically performed when an homoduplex
peak was observed with a DNA sample. The mixture was
denatured at 94 -C for 7 min and reannealed at 55 -C for 40
min. After dHPLC analysis of the mixture, the observation
Table 2
Genotype and allele frequencies in NGT, IGT and CFRD CF patients
Gene/SNV Status Genotype frequency
11 /12 /22a %(n)
Allele 2
frequency (%)
TNF-a/-308 NGT 77.8(42) /18.5(11) /3.7(1) 12
IGT 84.8(28) /15.1(5) /0 7.6
CFRD 81.6(62) /18.4(14) /0 9.2 p =0.74
IL-18/-137 NGT 3.7(2) /35.2(19) /61.1(33) 78.7
IGT 3(1) /30.3(10) /66.7 81.8
CFRD 3.9(3) /34.2(26) /61.8(47) 79 p =0.98
PPARc/Ala12 NGT 75.9(41) /0 /24.1(13) 12
IGT 84.8(28) /0 /15.2(5) 7.6
CFRD 80.3(61) /1.3(1) /18.4(14) 9.9 p =0.77
Kir6.2/E23 NGT 7.4(4) /53.7(29) /38.9(21) 65.7
IGT 12.1(4) /63.6(21) /24.2 (8) 56.1
CFRD 6.6(5) /60.6(46) /32.9(25) 63.2 p =0.60
IL-6/-174 NGT 16.7(9) /40.7(22) /42.6(23) 37
IGT 21.2(7) /42.4(14) /36.4(12) 42.4
CFRD 14.5(11) /51.3(39) /34.2(26) 40.1 p =0.71
CAPN10/SNP-43 NGT 55.6(30) /38.9(21) /5.6(3) 79
IGT 51.5(17) /33.3(11) /15.2(5) 68
CFRD 47.4(36) /47.4(36) /5.3(4) 71 p =0.32
CAPN10/SNP-44 NGT 61.1(33) /35.2(19) /3.7(2) 78
IGT 51.5(17) /33.3(11) /15.2(5) 84
CFRD 79(60) /19.7(15) /1.3(1) 88 p =0.16
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presence of homozygote variant in the DNA sample.
1.3. Statistical analysis
Each polymorphism was tested to ensure that it fits
Hardy–Weinberg equilibrium. Differences in allele and
haplotype frequencies between the studied groups were
assessed by Fisher’s exact probability test. Odds ratios (OR)
and 95% confidence intervals (CI; adjusted for age and sex)
for diabetes were calculated by logistic regression analysis.
The standardized disequilibrium coefficient DVwas calculat-
ed for SNPs of the CAPN10 gene. Linkage disequilibrium
was checked by v2 test with Yate’s correction. A signifi-
cance level of 5% (two-sided) was used for the analyses. A
statistical method described by Stephens et al. has been used
to infer phase and to reconstruct haplotypes [26]. Variation
of BMI and %FEV1 within each group was expressed as the
meanTSD. Statistically significant differences among
groups were analysed by standard analysis of variance
methods.CAPN10/SNP-19 NGT 27.8(15) /40.7(22) /31.5(17) 51
IGT 6.1(2) /36.4(12) /57.6(19) 75
CFRD 15.8(12) /40.8(31) /43.4(33) 63 p =0.05
a TNF-a: 1= -308 A; 2=-308 G; IL-18: 1=-137C; 2=-137G; PPARc:
1=Pro12; 2=Ala12; Kir6.2: 1=K23; 2=E23; IL-6: 1= -174G; 2=-174 C;
CAPN10: UCSNP-43: 1=G; 2=A; UCSNP-44: 1=T; 2=C; SNP-19: 1=2
copies; 2=3 copies.2. Results and discussion
The use of the OGTT allowed the 163 CF patients to be
categorized into normal, impaired and diabetic glucose
tolerance groups. Normal glucose tolerance was detected in
54 (33%) of the 163 CF patients, glucose intolerance in 33
(20%) patients and CFRD in 76 (47%). The prevalence of
IGT and diabetes mellitus increased with age: patients with
IGT (29.6T6.9 years) and diabetes mellitus (29.5T6.3
years) were significantly older than patients with NGT
(26.2T6.4 years) ( p =0.01). No gender differences were
observed between the three groups ( p =0.92). There were
no significant differences in the BMI among the three
groups (Table 1). However, there were statistically signif-
icant differences in FEV1 among the three glucose tolerance
groups. FEV1 was significantly lower in patients with
CFRD than in patients with IGT and NGT ( p =0.03 and
p =0.0005, respectively) (Table 1). Similar results were
obtained in a previous prospective study of 152 patients
with CF [27]. In this previous study, Milla et al. showed that
the degree of glucose intolerance and the degree of
deficiency in insulin secretion are a strong determinant ofTable 1
Clinical characteristics of the patients at entry by standard oral glucose
tolerance test
NGT IGT CFRD p value
FEV1, % predicted 51.3T25.1 46.3T25.8 36.4T19.5 p =0.002
BMI, kg/m2 18.5T1.7 19.3T3.1 18.9T2.4 p =0.2
Data are given as meansTSD. p values are given for comparison of all three
groups. FEV1: Forced expiratory volume in 1 s; BMI: body mass index;
NGT: normal glucose tolerance, IGT: impaired glucose tolerance; CFRD:
CF-related diabetes mellitus.future lung function decline in patients with CF [27]. No
difference in the distribution of the CFTR genotype were
observed between the three groups ( p=0.31). Table 2 shows
the distribution of alleles and genotypes in the different
studied genes in NGT, IGT and CFRD groups. Except one
polymorphism (UCSNP-19) located in the CAPN10 gene all
allele and genotype distributions were similar in the three
groups. All genotype distributions were comparable with
those reported in other Caucasian populations.
Our results suggest the first evidence for the association
between CFRD and UCSNP-19 polymorphism in the
CAPN10 gene. This 2-allele polymorphism consists of 2
(allele 1) or 3 copies (allele 2) of 32-bp sequence at
nucleotide 7917. The CAPN10 genotype distribution
differed significantly between NGT, IGT and CFRD groups.
The difference reflected a decrease in the 11 genotype and
an increase in the 22 genotype in the CAPN10 gene in IGT
and CFRD patients ( p =0.05). Odds ratio for the homozy-
gote 22 versus homozygote 11 was 3.4 (95% confidence
interval=1.21–9.45) ( p=0.02). Although the p value of
0.05 is quite modest, our result suggests that the genotype
22 predisposes an CF individual to developing CFRD. A
false positive association due to population stratification is
unlikely, because all the patients included in this study
belonged to the same ethnic group.
The haplotypes of CAPN10 gene for all subjects were
reconstructed using the statistical method described by
S. Derbel et al. / Journal of Cystic Fibrosis 5 (2006) 47–5150Stephens et al. [26]. UCSNP-44 (1=C, 2=T), -43 (1=G,
2=A) and -19 (1=2 copies, 2=3 copies) polymorphisms
were used to define the most common haplotypes.
Linkage disequilibrium was used to reduce the variability
of haplotypes. That reduced the number of eight theoret-
ical haplotypes to four (i.e. 111 (21%); 112 (35%), 122
(26%) and 211 (14%)). Frequencies of haplotypes in
CAPN10 are shown in Table 3. Glucose intolerance
tended to be higher in those with haplogenotype 112/
112 than in those with other haplogenotypes, but the
differences were not statistically significant (27.3% IGT
and 14.5% CFRD versus 9.2% NGT). This haplogenotype
has previously been associated with type 2 diabetes in a
Finnish population [23].
Recent experimental data give biological credibility for
the involvement of calpain 10 as a predisposition gene in
CFRD [28]. Calpain 10 is a 672 amino-acid nonlysosomal
cysteine intracellular protease and an atypical calpain in
that domain IV of typical calpain has been replaced with a
domain III-like structure. Its protease domain is followed
by a tandem repeat of two domains similar to domain III.
The extreme COOH-terminal III-like domain (IIIV) was
originally called domain T, but is now regarded as a III-
like domain [29]. Calpain 10 is expressed ubiquitously in
all adult and foetal human tissues examined, and similar
ubiquitous expression has been confirmed in rat and
mouse. The message level varies with tissues but is
highest in the heart, followed by the brain, liver, kidney,
and pancreas in humans [29]. Interestingly, Ca2+ affects
the expression level and subcellular distribution of calpain
10 in rat cultured lens epithelial cells suggesting that
calpain 10 is responsive to Ca2+. Recently, using
immunolocalization, in conjunction with a well-character-
ized anticalpain-10 antibody that has no observed cross-
reactivity with other calpain species, Marshall et al. have
shown that in human pancreas, calpain 10 is only
expressed in islet cells and not in either the exocrine
pancreas or ductal tissue [28]. Interestingly, they have
shown that calpain 10 overexpression has a significant
impact in increasing the extent of Ca2+-dependentTable 3
Frequencies of the most frequent CAPN10-haplotype (UCSNP-44, -43 and
-19) in the three groups of NGT, IGT and CFRD CF patients
Haplotypes Groups -44 -43 -19 Frequency (%)
111 NGT T G del 23.1
IGT T G del 10.6
CFRD T G del 24.3
211 NGT C G del 20.4
IGT C G del 10.6
CFRD C G del 11.2
112 NGT T G ins 30.6
IGT T G ins 42.4
CFRD T G ins 35.5
122 NGT T A ins 20.4
IGT T A ins 28.8
CFRD T A ins 28.3stimulated insulin secretion in pancreatic h-cells. In h-
cells granule exocytosis is mediated by the vesicle-
associated membrane protein VAMP2 tethering granules
to the plasma membrane through interaction with the t-
SNARE syntaxin 1 and SNAP-25. Direct interaction
between at least one isoform of calpain 10 and the t-
SNAREs (SNAP-25, syntaxin 1) suggests that calpain 10
is an important component of the exocytotic granule
fusion machinery complex. Under nonstimulating condi-
tions, the complex of SNAP-25, VAMP2, syntaxin 1 and
unactivated calpain 10 anchors the granule to the plasma
membrane, with intact SNAP-25 also inhibiting fusion of
the granule and membrane. Secretagogue stimulation
causes membrane depolarization, the associated opening
of Lc-type Ca2+ channels, and the resultant influx of
extracellular Ca2+ which activates calpain 10. The enzyme
then cleaves SNAP-25 in a region adjacent to the N
terminus. It results in the removal of complex from the
membrane facilitating the membrane–membrane contact
and the granule fusion. The link between calpain 10 and
insulin secretion gives biological credibility for the
involvement of calpain 10 as a predisposition gene in
CFRD. However, the mechanism by which SNP-19 in
CAPN10 affects glucose metabolism and insulin secretion
is undetermined. In the SNP-43, genotype 11 was shown
to associate with reduced calpain-10 mRNA expression in
skeletal muscle and decreased glucose oxidation [18]. It is
possible that SNP-19 polymorphism also influences
calpain-10 mRNA levels because the number of tandem
repeats affects transcription and protein expression levels.
For example, in the insertion/deletion polymorphism of
the angiotensin I converting enzyme (ACE), the homozy-
gote for insertion had the lowest plasma ACE levels [30].
The finding for CAPN10 is also biologically plausible
because SNP-19 was reported to affect insulin sensitivity
in Caucasian with northern European ancestry [31]. In
other racial groups such as the Japanese population,
UCSNP-19 genotype 22 was associated with increased
body mass index and HbA1c levels [32]. In this previous
study of 286 Japanese subjects (207 men and 79 women,
49.3T8.1 years) who visited the general health check-up
center of the Toronomon hospital in May 1995, haploge-
notype 121/121 (UCSNP 43/19/63) was significantly
associated with an increase in BMI, and subjects with this
haplogenotype tended to have higher HbA1c levels than
those with other haplogenotypes [32]. Therefore, this
association implied the contribution of this SNP to
susceptibility to glucose intolerance and obesity at least
in the Japanese general population.
In conclusion, though functional neighbouring polymor-
phism could not be excluded, our observations suggest that
SNP-19 of CAPN10 could be involved in the pathogenesis
of diabetes in cystic fibrosis. Additional genetic epidemio-
logic and functional studies will help to further clarify the
potentially important role of CAPN10 polymorphism in
diabetes.
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